Details for New Drug Application (NDA): 208336
✉ Email this page to a colleague
NDA 208336 describes LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, which is a drug marketed by Dr Reddys, MSN, Sunshine, and Zydus Pharms, and is included in four NDAs. It is available from one supplier. Additional details are available on the LINAGLIPTIN AND METFORMIN HYDROCHLORIDE profile page.
The generic ingredient in LINAGLIPTIN AND METFORMIN HYDROCHLORIDE is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
The generic ingredient in LINAGLIPTIN AND METFORMIN HYDROCHLORIDE is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
Summary for 208336
| Tradename: | LINAGLIPTIN AND METFORMIN HYDROCHLORIDE |
| Applicant: | Sunshine |
| Ingredient: | linagliptin; metformin hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG;500MG | ||||
| Approval Date: | Aug 30, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG;850MG | ||||
| Approval Date: | Aug 30, 2021 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG;1GM | ||||
| Approval Date: | Aug 30, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
